RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling

Abstract

Receptor activator of nuclear factor kappa B-ligand (RANKL), its receptor RANK, and osteoprotegerin which binds RANKL and acts as a soluble decoy receptor, are essential controllers of bone remodeling. They also play important roles in establishing immune tolerance and in the development of the lymphatic system and mammary glands. In bone, RANKL stimulates osteoclast formation by binding RANK on osteoclast precursors and osteoclasts. This is required for bone resorption. Recently, RANKL and RANK have been shown to be functional components of extracellular vesicles (EVs). Data linking RANKL and RANK in EVs to biological regulatory roles are reviewed, and crucial unanswered questions are examined. RANKL and RANK are transmembrane proteins and their presence in EVs allows them to act at a distance from their cell of origin. Because RANKL-bearing osteocytes and osteoblasts are often spatially distant from RANK-containing osteoclasts in vivo, this may be crucial for the stimulation of osteoclast formation and bone resorption. RANK in EVs from osteoclasts has the capacity to stimulate a RANKL reverse signaling pathway in osteoblasts that promotes bone formation. This serves to couple bone resorption with bone formation and has inspired novel bifunctional therapeutic agents. RANKL- and RANK- containing EVs in serum may serve as biomarkers for bone and immune pathologies. In summary, EVs containing RANKL and RANK have been identified as intercellular regulators in bone biology. They add complexity to the central signaling network responsible for maintaining bone. RANKL- and RANK-containing EVs are attractive as drug targets and as biomarkers.

Keywords

Cell signaling / osteoclast / osteoblast / osteocyte / exosome / microvesicle / coupling factor / apoptotic vesicle

References

[1] Boyce BF.Functions of RANKL/RANK/OPG in bone modeling and remodeling.Arch Biochem Biophys2008;473:139-46 PMCID:PMC2413418

[2] Lacey D,Tan H.Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell1998;93:165-76

[3] Yasuda H,Nakagawa N.Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad Sci U S A1998;95:3597-602 PMCID:PMC19881

[4] Kong YY,Sarosi I.OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature 1999;397:315-23

[5] Fata JE,Li J.The Osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.Cell2000;103:41-50

[6] Nagy V.The RANKL-RANK story.Gerontology2015;61:534-42

[7] Compston JE,Leslie WD.Osteoporosis.Lancet2019;393:364-76

[8] Bone HG,Brandi ML.10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.Lancet Diabetes Endocrinol2017;5:513-23

[9] Lipton A,Stopeck AT.Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.Eur J Cancer2016;53:75-83

[10] Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[11] Mathieu M,Lavieu G.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication.Nat Cell Biol2019;21:9-17

[12] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[13] Caruso S.Apoptotic cell-derived extracellular vesicles: more than just debris.Front Immunol2018;9:1486 PMCID:PMC6031707

[14] Deng L,Peng Y.Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts.Bone2015;79:37-42

[15] Huynh N,Smith D.Characterization of regulatory extracellular vesicles from osteoclasts.J Dent Res2016;95:673-9 PMCID:PMC4924543

[16] Killock D.Bone: Osteocyte RANKL in bone homeostasis: a paradigm shift?.Nat Rev Rheumatol2011;7:619

[17] Nakashima T,Fukunaga T.Evidence for osteocyte regulation of bone homeostasis through RANKL expression.Nat Med2011;17:1231-4

[18] Xiong J.Osteocyte RANKL: new insights into the control of bone remodeling.J Bone Miner Res2012;27:499-505 PMCID:PMC3449092

[19] Kong YY,Penninger JM.Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development.Immunol Cell Biol1999;77:188-93

[20] Kong Y,Penninger JM.Osteoprotegerin ligand: a regulator of immune responses and bone physiology.Immunology Today2000;21:495-502

[21] Hanada R,Hanada T.Central control of fever and female body temperature by RANKL/RANK.Nature2009;462:505-9

[22] Serrano EM,Zuo J,Manolson MF.Regulation of vacuolar H(+)-ATPase in microglia by RANKL.Biochem Biophys Res Commun2009;389:193-7 PMCID:PMC2758416

[23] Hanada R.The role of the RANKL/RANK/OPG system in the central nervous systems (CNS).J Bone Miner Metab2020;

[24] Ikebuchi Y,Honma M.Coupling of bone resorption and formation by RANKL reverse signalling.Nature2018;561:195-200

[25] Liu C,Huang P.Structural and functional insights of RANKL-RANK interaction and signaling.J Immunol2010;184:6910-9

[26] Pan B,To LB.The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).J Bone Miner Res2004;19:147-54

[27] Hikita A,Wakeyama H.Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand.J Biol Chem2006;281:36846-55

[28] Lynch CC,Acuff HB.MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.Cancer Cell2005;7:485-96

[29] Asano T,Nakai Y.Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone.Nat Metab2019;1:868-75

[30] Cappariello A,Muraca M,Rucci N.Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone.J Bone Miner Res2018;33:517-33

[31] Kobayashi-Sun J,Kondo M.Uptake of osteoblast-derived extracellular vesicles promotes the differentiation of osteoclasts in the zebrafish scale.Commun Biol2020;3:190 PMCID:PMC7181839

[32] Huang X,Liu J,Cen X.MicroRNAs-containing extracellular vesicles in bone remodeling: an emerging frontier.Life Sci 2020;254:117809

[33] Eichholz KF,Riffault M.Human bone marrow stem/stromal cell osteogenesis is regulated via mechanically activated osteocyte-derived extracellular vesicles.Stem Cells Transl Med2020;9:1431-47 PMCID:PMC7581449

[34] Morrell AE,Robinson ST.Mechanically induced Ca²⁺ oscillations in osteocytes release extracellular vesicles and enhance bone formation.Bone Res2018;6:6 PMCID:PMC5859015

[35] Qin Y,Zhao W.Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: A novel mechanism in muscle-bone communication.J Biol Chem2017;292:11021-33 PMCID:PMC5491785

[36] Lv PY,Tian GJ.Osteocyte-derived exosomes induced by mechanical strain promote human periodontal ligament stem cell proliferation and osteogenic differentiation via the miR-181b-5p/PTEN/AKT signaling pathway.Stem Cell Res Ther2020;11:295 PMCID:PMC7367226

[37] Sato M,Kawano M.Circulating osteocyte-derived exosomes contain miRNAs which are enriched in exosomes from MLO-Y4 cells.Biomed Rep2017;6:223-31 PMCID:PMC5351302

[38] Yan Y,Ge L.Osteocyte-mediated translation of mechanical stimuli to cellular signaling and its role in bone and non-bone-related clinical complications.Curr Osteoporos Rep2020;18:67-80

[39] Holliday LS,Zuo J,Neubert JK.Exosomes: novel regulators of bone remodelling and potential therapeutic agents for orthodontics.Orthod Craniofac Res2017;20 Suppl 1:95-9 PMCID:PMC5484069

[40] Li D,Guo B.Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation.Nat Commun2016;7:10872 PMCID:PMC4786676

[41] Sun W,Li Y.Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity.Cell Discov2016;2:16015 PMCID:PMC4886818

[42] Marton N,Baricza E.Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies.Cell Mol Life Sci2017;74:3599-611

[43] Okada E,Yamamoto M,Kuroda S.Indirect osteoblast differentiation by liposomal clodronate.J Cell Mol Med2018;22:1127-37 PMCID:PMC5783836

[44] de Menezes EG, Ramallho J, Bucovsky M, Shane E, Yin MT, Norris PJ. Serum extracellular vesicles expressing bone activity markers associate with bone loss after HIV antiretroviral therapy.AIDS2020;34:351-61 PMCID:PMC7983839

[45] Sims NA.Osteoclasts Provide Coupling signals to osteoblast lineage cells through multiple mechanisms.Annu Rev Physiol2020;82:507-29

[46] Rody WJ Jr,Emory-Carter AK.The proteome of extracellular vesicles released by clastic cells differs based on their substrate.PLoS One2019;14:e0219602 PMCID:PMC6619814

[47] Arana-Chavez VE.Clastic cells: mineralized tissue resorption in health and disease.Int J Biochem Cell Biol2009;41:446-50

[48] Wang Z.Osteoclasts and odontoclasts: signaling pathways to development and disease.Oral Dis2011;17:129-42

[49] Linde A.Dentin matrix proteins: composition and possible functions in calcification.Anat Rec1989;224:154-66

[50] Bullock WA,Robling AG.Osteocytes and mechanical loading: the Wnt connection.Orthod Craniofac Res2019;22 Suppl 1:175-9

[51] Dodge T,Ayoub R.Mechanical loading, damping, and load-driven bone formation in mouse tibiae.Bone2012;51:810-8 PMCID:PMC3580058

[52] Xia WF,Xiong L.Vps35 loss promotes hyperresorptive osteoclastogenesis and osteoporosis via sustained RANKL signaling.J Cell Biol2013;200:821-37 PMCID:PMC3601351

[53] Bourron O,Diallo MH.Circulating receptor activator of nuclear factor kB ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study.Cardiovasc Diabetol2020;19:140 PMCID:PMC7501627

[54] Ma Q,Wu Y.Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling.J Biol Chem2019;294:11240-7 PMCID:PMC6643026

[55] Stepan JJ,Boivin G,Lakatos P.Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.Endocr Regul2003;37:225-38

[56] Pegtel DM.Exosomes.Annu Rev Biochem2019;88:487-514

[57] Peinado H,Matei IR.Pre-metastatic niches: organ-specific homes for metastases.Nat Rev Cancer2017;17:302-17

[58] Loftus A,George C.Extracellular vesicles from osteotropic breast cancer cells affect bone resident cells.J Bone Miner Res2020;35:396-412

[59] Dovio A,Angeli A.Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?.J Endocrinol Invest2005;28 Suppl 10:14-22

[60] Eleutherakis-Papaiakovou E,Gavriatopoulou M.Circulating soluble receptor activator of nuclear factor kappa B ligand and C-C motif ligand 3 correlate with survival in patients with waldenström macroglobulinemia.Clin Lymphoma Myeloma Leuk2018;18:431-7

[61] Granchi D,Amato I,Baldini N.Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.Int J Cancer2006;119:146-51

[62] Oh KW,Lee WY.Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.Clin Endocrinol (Oxf)2005;62:92-8

[63] Raaz-Schrauder D,Stumpf C.Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.Heart Vessels2017;32:1304-13

[64] Sarink D,Johnson T.Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.BMC Cancer2018;18:1010 PMCID:PMC6196438

[65] Zaman T,Narod SA,Kotsopoulos J.Plasma RANKL levels are not associated with breast cancer risk in.BRCA12016;10:2475-83 PMCID:PMC5349945